Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Sponsor: Northwestern University
Summary
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-01-16
Completion Date
2026-09-30
Last Updated
2025-07-28
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin 10 MG [Farxiga]
10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
Locations (1)
Northwestern University
Chicago, Illinois, United States